Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Epithelium-on photorefractive intrastromal cross-linking (PiXL) for correction of low myopia in Asian eyes

Search Title by author or title

Session Details

Session Title: Cross-Linking

Session Date/Time: Tuesday 10/10/2017 | 14:00-16:30

Paper Time: 14:50

Venue: Room 4.6

First Author: : W.Lim SINGAPORE

Co Author(s): :    J. Theng   Z. Soh   H. Choi              

Abstract Details


To report the 12 months clinical evaluation of Epithelium-On PiXL for the correction of low myopia.


Mount Alvernia Hospital, Singapore


Myopic patients with normal (non-ectatic) corneas underwent the PiXL procedure for correction of low myopia. PiXL treatments were delivered through the selective application of UVA light based on the refractive error of each patient. Clinical evaluation included safety (BCVA, ECC, CCT, anterior ocular health) and efficacy (UCVA, manifest refraction, K-mean) examinations. In addition, a survey was conducted at 12 months post-procedure to evaluate patients’ subjective experience with the procedure.


14 myopic eyes (mean MRSE -1.62 ± 0.6D; range -0.75 to -2.65D) of 8 subjects (mean age 30 years old; range 24 to 51 years old) were enrolled in the study. At 12 months post, mean MRSE reduction of 0.72 ± 0.43D was observed, with a corresponding gain in UCVA of 0.25 logMAR and mean K-mean flattening of 0.36 ± 0.23D. All patients achieved BCVA of 20/20 or better from 1 month onwards. There were no cases of ocular infection or secondary changes to the crystalline lens and retina due to UV exposure, while transient corneal haze subsided gradually.


The epithelium-on PiXL procedure was safe and effective at reducing myopic refractive error in this study with up to 12 months follow-up. Early results of this novel application of collagen cross-linking are encouraging but longer-term data in larger studies are required.

Financial Disclosure:


Back to previous